IgLON Family Member 5 (IgLON5) Antibody, IgG by CBA-IFA With Reflex to Titer, Serum
Also known as: IGLON5 SER
Use
This test aids in the diagnosis of neurodegenerative disease and limbic encephalitis. It may also be used to monitor treatment response in individuals who are antibody positive. The presence of IgLON5 antibodies can be associated with conditions such as sleep disorders, bulbar symptoms, gait problems, cognitive dysfunction, movement disorders, and dysautonomia. IgLON5 autoimmune neurologic/neurodegenerative disorders may be paraneoplastic, though the associated tumor type is variable.
Special Instructions
If the initial IgLON5 antibody IgG is positive, an IgG titer will be reflexively added for further analysis, with additional charges applied accordingly.
Limitations
A negative test result does not necessarily rule out a diagnosis of an autoimmune neurologic disorder. The interpretation of any antineural antibody test requires clinical correlation. This test was developed and its performance characteristics determined by ARUP Laboratories and is intended for clinical purposes. It has not been cleared or approved by the U.S. Food and Drug Administration.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 96478-3
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.2 mL
Container
ARUP standard transport tube
Collection Instructions
Separate serum from cells within 2 hours of collection.
Causes for Rejection
CSF or plasma, contaminated, grossly hemolyzed, icteric, or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month |